Amgen (AMGN) Submits sNDA for Kyprolis in Relapsed Multiple Myeloma
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE